批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/02/01 |
SUPPL-50(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/06/09 |
SUPPL-49(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2020/12/23 |
SUPPL-48(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/06/11 |
SUPPL-46(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/07/11 |
SUPPL-44(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/11/03 |
SUPPL-43(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/11/04 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
2010/10/27 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/10/14 |
SUPPL-39(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2009/02/06 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/05/30 |
SUPPL-33(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/08/25 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/02/11 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1998/12/03 |
SUPPL-25(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1998/04/07 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1997/03/27 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1996/10/15 |
SUPPL-24(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1993/08/09 |
SUPPL-21(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1993/05/18 |
SUPPL-15(补充) |
Approval |
Efficacy |
|
|
|
1988/05/13 |
SUPPL-19(补充) |
Approval |
Labeling |
|
|
|
1987/06/12 |
SUPPL-16(补充) |
Approval |
Labeling |
|
|
|
1987/06/12 |
SUPPL-12(补充) |
Approval |
Labeling |
|
|
|
1982/11/18 |
SUPPL-13(补充) |
Approval |
Labeling |
|
|
|
1980/04/25 |
SUPPL-10(补充) |
Approval |
Labeling |
|
|
|
1979/12/17 |
SUPPL-11(补充) |
Approval |
Labeling |
|
|
|
1978/01/03 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1973/11/23 |
SUPPL-6(补充) |
Approval |
Supplement |
STANDARD
|
|
|
1953/12/23 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:NITROFURANTOIN 剂型/给药途径:SUSPENSION;ORAL 规格:25MG/5ML 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
009175 |
001 |
NDA |
FURADANTIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
Yes |
No |
AB |
Approved Prior to Jan 1, 1982
|
CASPER PHARMA LLC |
201679 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2011/05/11
|
AMNEAL PHARMS |
201355 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2013/08/14
|
NOSTRUM LABS INC |
201693 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2014/09/08
|
NOVEL LABS INC |
205180 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2016/05/03
|
ACTAVIS MID ATLANTIC |
216385 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2023/04/14
|
NOVITIUM PHARMA |
212607 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2023/05/11
|
AUROBINDO PHARMA |
218346 |
001 |
ANDA |
NITROFURANTOIN |
NITROFURANTOIN |
SUSPENSION;ORAL |
25MG/5ML |
Prescription |
No |
No |
AB |
2024/10/28
|
BIOCON PHARMA |